Visterra is a biologics research and early-stage clinical development company developing therapies for patients with immune-mediated and other hard-to-treat diseases.
Ready to make a meaningful impact?
At Visterra, we champion innovation, teamwork, and perseverance.
You’ll be challenged and empowered to make meaningful impacts as a member of a collaborative, high-performing, agile team.
Our approach is unique.
At Visterra, we believe innovative technologies and approaches are critical to developing novel therapeutics – from cutting-edge computational, AI, and experimental research methods to agile preclinical development, reliable manufacturing, and creative trial designs.
Immunoglobulin A
Nephropathy (IgAN)
Sibeprenlimab (VIS649) is an investigational humanized IgG2 monoclonal antibody being evaluated for the treatment of IgA nephropathy (IgAN), a chronic, progressive kidney disease.
Rowley, Kirk
“Visterra is a company where great people and great science converge. I’m motivated by the challenges of identifying therapies for difficult-to-treat diseases and the continuous learning opportunities the company provides.” – Kirk Rowley, Principal Scientist, Research
“Visterra is a company where great people and great science converge. I’m motivated by the challenges of identifying therapies for difficult-to-treat diseases and the continuous learning opportunities the company provides.”
– Kirk Rowley, Principal Scientist, Research
Committed to extending and improving the lives of people afflicted with immune-mediated diseases.
Our team is fueled by curiosity, guided by the scientific method and innovative clinical research strategies, culminating in novel therapies engineered to augment and surpass standard of care.
